Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sandoz generic divestitures

Executive Summary

Sandoz and Eon will divest three generic drugs as part of Novartis' acquisition of Eon: Sandoz' desipramine and orphenadrine, and Eon's rifampin. Together, the three products generated 2004 revenue of less than $5 mil., Sandoz said. The divestitures are expected to close July 22. The Federal Trade Commission is continuing to review the acquisition; Novartis has submitted a second response to the agency, and the deal is expected to close by the end of July. Novartis announced its $8.76 bil. acquisition of Eon and Hexal in February (1"The Pink Sheet" Feb. 28, 2005, p. 21)...
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

PS046099

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel